[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499765":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":26,"locations":27,"responsibleParty":46,"collaborators":26,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":26,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":30,"whyStopped":26,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The Trial group","EXPERIMENTAL","we will prolong the duration of vaginal progesterone treatment until 24 weeks of gestation.",[13],"Drug: Progesterone Sustained-release vaginal gel",{"label":15,"type":10,"description":16,"interventionNames":17},"The control group","we will use vaginal progesterone treatment until 12 weeks of gestation.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Progesterone Sustained-release vaginal gel","the treatment time of vaginal progesterone",[9,15],[25],"Vaginal progesterone",null,[28],{"facility":29,"status":30,"city":31,"state":26,"zip":26,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Sun Yat-sen Memorial Hospital","RECRUITING","Guangzhou","China","CN",{"type":35,"coordinates":36},"Point",[37,38],113.25,23.11667,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":44,"phoneExt":26,"email":45},"Hui Chen","CONTACT","86-020-81332233","zheling76@163.com",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","chenhui79","Professor","100499765","phase-4-prolonged-progesterone-to-prevent-preterm-birth-from-ivf---et-100499765",false,"NCT05787509","Prolonged Progesterone to Prevent Preterm Birth From IVF - ET","The Exploration of Prolonged Treatment With Vaginal Progesterone to Prevent Preterm Birth From IVF Fresh Embryo Transplantation Cycle: a Randomized Controlled Trial","Inclusion criteria are: age 20-40 years; meeting the indications for assisted reproductive technology (ART) and undergoing fresh embryo transfer with in vitro fertilization (IVF); singleton pregnancy; and willingness to participate and provide written informed consent.\n\nExclusion criteria are: age \\>40 years; history of second-trimester miscarriage or cervical insufficiency; ovarian dysfunction or relevant surgical history; uterine malformation; diseases associated with abnormal uterine cavity morphology; abnormal cervical morphology or function, or history of cervical surgery; refractory vaginitis; multiple pregnancy; concomitant severe medical or surgical diseases; participation in another clinical trial within 90 days prior to randomization, or use of an investigational drug within 30 days; inability to complete long-term follow-up or poor compliance; and any other condition that, in the investigator's judgment, may affect trial implementation or outcome evaluation.",true,"FEMALE","20 Years","40 Years",{"count":62,"type":63},100,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","To investigate the incidence of preterm birth in IVF fresh embryo transplantation cycle patients after prolonged vaginal progesterone treatment",[69],"Preterm Birth","2026-06-08",{"date":72,"type":73},"2026-06-11","ACTUAL",{"date":75,"type":73},"2023-04-01",{"date":77,"type":63},"2029-04-30",{"name":5,"class":6},1]